Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMITABHA MAZUMDER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1881682318
CMS profile
84992
Location
DOWNEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$84,897.21

165 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMITABHA MAZUMDER

NPI 1881682318 · CMS profile ID 84992

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DOWNEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881682318?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMITABHA MAZUMDER, NPI 1881682318, CMS profile ID 84992. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881682318?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AMITABHA MAZUMDER, NPI 1881682318, CMS profile ID 84992. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881682318?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AMITABHA MAZUMDER, NPI 1881682318, CMS profile ID 84992, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881682318?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

165 matching records · $84,897.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 165 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 165.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $175.6909/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169999 CMS
Incyte Corporation $16.8809/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666248359 CMS
Amgen Inc. $147.2909/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169997 CMS
Janssen Biotech, Inc. $39.6209/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584046 CMS
Amgen Inc. $80.2109/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169973 CMS
PFIZER INC. $20.5109/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672938057 CMS
Amgen Inc. $287.6009/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169987 CMS
E.R. Squibb & Sons, L.L.C. $19.2609/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651246393 CMS
E.R. Squibb & Sons, L.L.C. $19.6309/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651246395 CMS
Seattle Genetics, Inc. $21.1509/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678793851 CMS
Amgen Inc. $33.4908/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169967 CMS
Amgen Inc. $134.9608/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169989 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.6408/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628479479 CMS
Novartis Pharmaceuticals Corporation $15.3808/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764717 CMS
Novartis Pharmaceuticals Corporation $13.3208/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764703 CMS
Amgen Inc. $29.4608/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662169965 CMS
PFIZER INC. $17.1408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672543531 CMS
Janssen Biotech, Inc. $3,300.0008/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584042 CMS
Verastem, Inc. $24.8408/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699798017 CMS
GENZYME CORPORATION $17.2808/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694107333 CMS
Takeda Pharmaceuticals U.S.A., Inc. $610.5008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697373599 CMS
Novartis Pharmaceuticals Corporation $18.7208/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764727 CMS
Janssen Biotech, Inc. $408.3007/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584033 CMS
Janssen Biotech, Inc. $121.6707/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584038 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,000.0007/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377189 CMS
Takeda Pharmaceuticals U.S.A., Inc. $116.9107/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697379495 CMS
Novartis Pharmaceuticals Corporation $7.1007/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764733 CMS
Novartis Pharmaceuticals Corporation $20.3107/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764725 CMS
Merck Sharp & Dohme Corporation $19.5807/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695663911 CMS
Rigel Pharmaceuticals, Inc. $16.4407/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698991261 CMS
AstraZeneca Pharmaceuticals LP $23.5006/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685654731 CMS
Lilly USA, LLC $18.3606/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657670403 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,310.0006/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697374395 CMS
Janssen Biotech, Inc. $3,300.0006/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584029 CMS
Novartis Pharmaceuticals Corporation $18.5506/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764713 CMS
Janssen Biotech, Inc. $25.4706/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584026 CMS
AstraZeneca Pharmaceuticals LP $19.2406/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685898009 CMS
Janssen Biotech, Inc. $408.3006/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584019 CMS
Janssen Biotech, Inc. $104.1606/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584023 CMS
E.R. Squibb & Sons, L.L.C. $11.0005/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651246381 CMS
Janssen Biotech, Inc. $3,800.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584015 CMS
Amgen Inc. $29.1705/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662170021 CMS
Takeda Pharmaceuticals U.S.A., Inc. $215.8105/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697373649 CMS
Novartis Pharmaceuticals Corporation $22.2305/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764695 CMS
Janssen Biotech, Inc. $169.4805/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584009 CMS
Janssen Biotech, Inc. $69.0205/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584011 CMS
Ipsen Biopharmaceuticals, Inc $15.8805/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640636921 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.0205/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628480285 CMS
Janssen Biotech, Inc. $500.0005/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658584005 CMS
Novartis Pharmaceuticals Corporation $21.3805/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764709 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84,897.21 165
PY2020 $35,719.17 120
PY2021 $31,614.85 123
PY2022 $22,415.70 152
PY2023 $19,837.46 180
PY2024 $5,997.55 204
PY2025 $6,517.05 163

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $652,892.48 63
PY2024 Principal investigator $731,460.59 29
PY2023 Principal investigator $46,779.39 16
PY2022 Principal investigator $38,552.46 9
PY2021 Principal investigator $1,536,887.31 12
PY2020 Principal investigator $8,025.00 7
PY2019 Principal investigator $5,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $402.00 12/19/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427449
Principal investigator 1 Janssen Research & Development, LLC $234.00 12/19/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427536
Principal investigator 1 GENZYME CORPORATION $2,288.00 12/15/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091749
Principal investigator 1 Janssen Research & Development, LLC $72.95 12/15/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427472
Principal investigator 1 Janssen Research & Development, LLC $1,706.00 12/15/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427488
Principal investigator 1 Janssen Research & Development, LLC $85.83 12/15/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427696
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,785.00 11/13/2025 Non-covered Recipient Entity
Helios Clinical Research
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1235996931
Principal investigator 1 Janssen Research & Development, LLC $2,901.00 11/07/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427758
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $60,516.14 11/03/2025 Non-covered Recipient Entity
Helios Clinical Research
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235996929
Principal investigator 1 Janssen Research & Development, LLC $63.19 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427422
Principal investigator 1 Janssen Research & Development, LLC $2,159.00 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427639
Principal investigator 1 Janssen Research & Development, LLC $12,137.00 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427689
Principal investigator 1 GENZYME CORPORATION $3,084.23 10/20/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091743
Principal investigator 1 GENZYME CORPORATION $418.27 10/14/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091735
Principal investigator 1 GENZYME CORPORATION $3,459.70 10/06/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091723
Principal investigator 1 Celgene Corporation $11,920.00 09/26/2025 Non-covered Recipient Entity
Helios Clinical Research
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222306947
Principal investigator 1 GENZYME CORPORATION $150.00 09/22/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091711
Principal investigator 1 Janssen Research & Development, LLC $75.82 09/15/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427627
Principal investigator 1 Janssen Research & Development, LLC $72.90 09/15/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427646
Principal investigator 1 Janssen Research & Development, LLC $1,775.00 09/01/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427416
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,599.76 08/19/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) No dispute reported 06/30/2026 1246786655
Principal investigator 1 Janssen Research & Development, LLC $12,137.00 08/04/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427621
Principal investigator 1 Janssen Research & Development, LLC $217.00 08/04/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427658
Principal investigator 1 Janssen Research & Development, LLC $217.00 08/04/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427668
Principal investigator 1 Janssen Research & Development, LLC $217.00 08/04/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427683
Principal investigator 1 Janssen Research & Development, LLC $76.79 07/28/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427442
Principal investigator 1 Janssen Research & Development, LLC $90.14 07/28/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427676
Principal investigator 1 Janssen Research & Development, LLC $64.55 07/28/2025 Non-covered Recipient Entity
HELIOS CR INC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175427721
Principal investigator 1 Celgene Corporation $31,147.05 07/09/2025 Non-covered Recipient Entity
The Oncology Institute Of Hope And Innovation
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222305638
Principal investigator 1 Janssen Research & Development, LLC $1,706.00 07/04/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369103
Principal investigator 1 GENZYME CORPORATION $190.69 07/02/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091705
Principal investigator 1 GENZYME CORPORATION $2,512.00 06/16/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091692
Principal investigator 1 Janssen Research & Development, LLC $1,069.00 05/26/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369052
Principal investigator 1 Janssen Research & Development, LLC $33.64 05/16/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175368986
Principal investigator 1 Janssen Research & Development, LLC $26.73 05/16/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369014
Principal investigator 1 Janssen Research & Development, LLC $26.80 05/16/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369044
Principal investigator 1 GENZYME CORPORATION $2,512.00 05/12/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091675
Principal investigator 1 GENZYME CORPORATION $173.46 05/12/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091680
Principal investigator 1 Celgene Corporation $89,372.55 05/05/2025 Non-covered Recipient Entity
The Oncology Institute Of Hope And Innovation
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222305470
Principal investigator 1 Janssen Research & Development, LLC $4,603.00 05/05/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369094
Principal investigator 1 GENZYME CORPORATION $366.48 04/28/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091669
Principal investigator 1 Janssen Research & Development, LLC $12,137.00 04/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369128
Principal investigator 1 Janssen Research & Development, LLC $28.74 04/22/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369144
Principal investigator 1 GENZYME CORPORATION $95.62 04/21/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091663
Principal investigator 1 Janssen Research & Development, LLC $57.60 04/07/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369037
Principal investigator 1 Janssen Research & Development, LLC $66.24 04/07/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369073
Principal investigator 1 Janssen Research & Development, LLC $67.02 04/07/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369174
Principal investigator 1 Janssen Research & Development, LLC $33.51 04/07/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369196
Principal investigator 1 Janssen Research & Development, LLC $24.95 04/07/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369202
Principal investigator 1 GENZYME CORPORATION $2,512.00 04/02/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091649
Principal investigator 1 Janssen Research & Development, LLC $8,141.00 03/31/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369059
Principal investigator 1 Janssen Research & Development, LLC $79.87 03/14/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369029
Principal investigator 1 Janssen Research & Development, LLC $3,871.00 03/10/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369111
Principal investigator 1 Janssen Research & Development, LLC $35.89 03/06/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369006
Principal investigator 1 Janssen Research & Development, LLC $28.72 03/06/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369153
Principal investigator 1 GENZYME CORPORATION $106.05 02/24/2025 Non-covered Recipient Entity
Toi Clinical Research
POC - Warm autoimmune hemolytic anemia No dispute reported 06/30/2026 1226091643
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,123.45 01/27/2025 Non-covered Recipient Entity
The Oncology Institute Of Hope And Innovation
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235993081
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $46,213.86 01/27/2025 Non-covered Recipient Entity
The Oncology Institute Of Hope And Innovation
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235993083
Principal investigator 1 Janssen Research & Development, LLC $64.37 01/23/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175368979
Principal investigator 1 Janssen Research & Development, LLC $60.63 01/23/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369021
Principal investigator 1 Janssen Research & Development, LLC $58.19 01/23/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369121
Principal investigator 1 Janssen Research & Development, LLC $53.67 01/23/2025 Non-covered Recipient Entity
TOI CLINICAL RESEARCH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175369159
Principal investigator 1 Novartis Pharmaceuticals Corporation $308,368.43 01/01/2025 Non-covered Recipient Entity
THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190303611